Audentes Therapeutics (BOLD) to be Acquired by Astellas Pharma for $60/share

Go back to Audentes Therapeutics (BOLD) to be Acquired by Astellas Pharma for $60/share

Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics

December 2, 2019 6:01 PM EST

- Complementary capabilities and resources of the two organizations create an industry-leading gene therapy company

- Audentes to operate as an independent subsidiary, with access to the global scientific and development resources of Astellas to accelerate product development and manufacturing expansion for the combined entity

- Acquisition price of US$60 per share in cash, representing a total equity value of approximately US$3 billion

- Transaction expected to be consummated in the first calendar quarter of 2020

TOKYO & SAN FRANCISCO--(BUSINESS WIRE)-- Astellas Pharma... More